source
- Novo Nordisk’s oral Wegovy sales beat forecasts, boosting shares over 5%BioPharma Dive’s latest visualization series examines how investors reacted to three drug launches highlighted in recent quarterly earnings. Novo Nordisk reported that its oral Wegovy generated 5.…
- Immunocore reports early data showing 70% two-year survival with brenetafusp/Kimmtrak combo in uveal melanomaImmunocore presented early clinical data on its bispecific T-cell engager combination brenetafusp and Kimmtrak in patients with uveal melanoma. The analysis, based on a subset of patients, indicat…